Legal Representation
Attorney
Albert P. Halluin
USPTO Deadlines
Application History
32 eventsDate | Code | Type | Description | Documents |
---|---|---|---|---|
Jan 18, 2011 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
Jan 17, 2011 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
May 26, 2010 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
May 25, 2010 | EX5G | S | SOU EXTENSION 5 GRANTED | Loading... |
May 17, 2010 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
May 17, 2010 | EXT5 | S | SOU EXTENSION 5 FILED | Loading... |
Dec 9, 2009 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
Dec 2, 2009 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
Dec 2, 2009 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
Jun 30, 2009 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
Jun 30, 2009 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
Jun 8, 2009 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
Jun 8, 2009 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
Dec 1, 2008 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
Dec 1, 2008 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
Dec 1, 2008 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
Jun 4, 2008 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
Jun 4, 2008 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
Jun 4, 2008 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
Dec 18, 2007 | NOAM | O | NOA MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
Sep 25, 2007 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
Sep 5, 2007 | NPUB | O | NOTICE OF PUBLICATION | Loading... |
Aug 20, 2007 | ALIE | A | ASSIGNED TO LIE | Loading... |
Aug 20, 2007 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
Jul 5, 2007 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
Jun 28, 2007 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
Jun 28, 2007 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
Jun 28, 2007 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
Dec 29, 2006 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
Dec 29, 2006 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
Dec 17, 2006 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Jul 26, 2006 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
medical diagnostic and therapeutic preparations, all for administration via diverse routes of administration including through the respiratory airways, and, medical devices for administering the pharmaceuticals, sold filled, the preparations including nucleotides, proteins and organic molecules for medical use, including macromolecules such as anti-sense oligonucleotides and enzymes and small and inorganic molecules for treatment of human and non-human animal respiratory, central nervous system, neoplastic, endocrine, immune and cardiovascular ailments, including bronchoconstriction, difficult breathing, impeded and obstructed lung airways, allergy(ies) and/or inflammation, which in some cases are adenosine receptor associated symptoms; pharmaceutical preparations for testing, and preventing and therapeutically treating respiratory, airway and pulmonary diseases and conditions, such as asthma, pulmonary vasconconstriction, inflammation, allergies, impeded respiration, acute respiratory disease syndrome (ards), renal damage and failure, ischemia resulting from the administration of certain drugs, including adenosine and other drugs for, for example, treating supra ventricular tachycardia (svt), adenosine stress tests, infantile respiratory distress syndrome (infantile rds), pain, cystic fibrosis, allergic rhinitis, allergic bronchitis, pulmonary hypertension, pulmonary vasconcontriction, emphysema, chronic obstructive pulmonary disease (copd), as well as cancers including leukemias, lymphomas, carcinomas, and the like, eg colon cancer, breast cancer, lung cancer, pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma, etc, as well as metastatic cancers, eg, cancers which metastasized to the lung(s), breast, liver and prostate
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
".COM"